<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Feb. 11, 2020 (HealthDay News) — For patients initiating therapy for advanced HIV, the addition of maraviroc, an antiretroviral drug with immunologic effects, to standard combined antiretroviral therapy (c-ART) does not improve clinical outcomes, according to a study published online Feb. 11 in the Annals of Internal Medicine<\/i>.<\/p>\n
Yves L\u00e9vy, M.D., Ph.D., from the Henri Mondor Hospital in Cr\u00e9teil, France, and colleagues conducted a randomized controlled trial to assess the benefit of adding maraviroc to standard c-ART for 416 patients with advanced disease at HIV diagnosis. The analyses included 409 participants who were randomly assigned to either the maraviroc group (202 patients) or a placebo group (207 patients) and who received more than one dose.<\/p>\n
The researchers found that the incidence of severe morbidity was 11.1 and 11.2 per 100 person-years in the maraviroc and placebo groups, respectively, during 72 weeks of follow-up (hazard ratio, 0.97; 95 percent confidence interval, 0.57 to 1.67). The incidence of grade 2 or higher adverse events was 36.1 versus 41.5 per 100 person-years (incidence rate ratio, 0.87; 95 percent confidence interval, 0.65 to 1.15).<\/p>\n
“Although new drug regimens are associated with better immunovirologic outcomes and may be associated with better clinical outcomes in HIV-1-infected persons presenting with advanced HIV infection, new strategies, such as host-directed therapies or improved prophylaxis, are clearly needed to decrease the higher morbidity and mortality observed in this population,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n